Betacar

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Betacar

Property Description
Active ingredient Atenolol
Form Oral tablet
Pharmacological class Beta-Adrenergic Receptor Antagonist (beta-blocker)
General purpose Cardiovascular support and systemic pressure regulation
Origin Synthetic chemical compound

Betacar is a synthetic, single-ingredient, prescription-only medication whose active component is the substance Atenolol. This drug is precisely classified as a Beta-Adrenergic Receptor Antagonist, more commonly known as a beta-blocker.

As an oral medication supplied in tablet form, Betacar belongs to a major class of cardiovascular agents. Atenolol is a second-generation, selective beta1-adrenergic antagonist, meaning the drug's primary action focuses on receptors in the heart. The chemical structure of Atenolol, documented under its International Nonproprietary Name (INN), confirms the drug's synthetic origin and single-compound composition.


The General Purpose of This Cardioselective Agent

The general purpose of Betacar is to support overall cardiovascular function by stabilizing heart activity and regulating systemic pressure. This is achieved because Atenolol acts as a cardioselective agent, meaning it primarily targets beta1 receptors found predominantly on the heart muscle.

This functional cardioselectivity is a differentiating factor, defining the drug's overall therapeutic role by focusing its effect on the heart's pumping and electrical activity. In settings where controlled cardiac output is required, such as managing chronic elevated systemic pressure, Atenolol serves to reduce cardiac workload. Consequently, Betacar is a foundational component in strategies intended to help patients maintain healthy, controlled blood pressure levels and alleviate cardiac stress.

Regulatory References

  1. NIH

What side effects are possible with Betacar?

Possible Side Effects and Safety Information

This section outlines the officially documented and clinically significant side effects and safety concerns associated with Betacar, based on regulatory reports and comprehensive post-marketing surveillance data.

Key Adverse Reaction Categories

Adverse reactions span multiple organ systems, with key concerns related to cardiovascular stability and gastrointestinal health. Reported reactions typically fall into categories such as:

  • Cardiovascular: Bradycardia (slow heart rate), hypotension (low blood pressure), and, less commonly, heart block.
  • Nervous System: Dizziness, fatigue, and insomnia.
  • Gastrointestinal: Nausea, abdominal discomfort, and, rarely, a severe form of enteropathy characterized by chronic, debilitating diarrhea with substantial weight loss.

Serious and Clinically Significant Risks

Regulatory authorities have noted specific, serious adverse events that require careful monitoring. A particular concern is the potential for sprue-like enteropathy, a delayed gastrointestinal reaction that may mimic celiac disease. Additionally, for drugs in this class, abrupt discontinuation can lead to acute exacerbation of angina, myocardial infarction, and arrhythmias, necessitating a gradual reduction under medical supervision.

Population-Specific Safety Considerations

Specific patient populations have documented safety caveats:

  • Diabetic Patients: The medication is not recommended for use to delay or prevent protein in the urine (microalbuminuria) in diabetic patients, as clinical trials did not support this benefit and raised cardiovascular safety questions in this setting.
  • Patients with Asthma/Bronchospasm: Use may be restricted in patients with pre-existing conditions that affect the airways, such as asthma, due to the potential for exacerbating bronchospasm.

Safety monitoring generally requires regular assessment of blood pressure and heart rate. The overall documented benefit of the drug, when used for its approved indication, is considered by regulatory agencies to outweigh its potential risks.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Betacar (Atenolol) overdose focuses on the manifestations of severe cardiovascular depression and systemic compromise.

Documented Overdose Manifestations

Overdose may present with exaggerated effects, including a critically slow heart rate (bradycardia), dangerously low blood pressure (hypotension), and hypoglycemia (low blood sugar). Other documented manifestations involve the respiratory system, such as bronchospasm and a disorder of respiratory drive, as well as neurological effects like lethargy.

Serious Outcomes and Emergency Action

Severe or life-threatening outcomes officially listed in regulatory documents include the progression to shock, convulsions (seizures), congestive heart failure, and coma. Immediate medical attention is required for any suspected overdose. Emergency services must be contacted immediately if the affected person collapses, has trouble breathing, experiences a seizure, or cannot be awakened.

Management and Antidote Status

Management is strictly symptomatic and supportive because no specific antidote is known. Officially documented emergency procedures to remove the unabsorbed drug include gastric lavage and the administration of activated charcoal. Hospital monitoring is necessary, often including ECG (electrocardiogram) and continuous measurement of vital signs. Hemodialysis is also a documented measure for drug removal. Low blood sugar is noted as a common nervous system symptom of this class of overdose in children.

Therapeutic Uses of Betacar

What Betacar Treats: Main Uses and Benefits

Betacar is commonly used across domains where additional symptomatic support is needed, addressing symptoms related to systemic imbalance and physical discomfort. Its therapeutic uses generally include the treatment of high blood pressure (hypertension), the management of symptoms related to physical discomfort such as chest pain (angina), and application in situations requiring short-term symptomatic support following an acute myocardial infarction.

The medication is commonly used as a treatment for the long-term management of chronic high blood pressure, providing support for sustained systemic pressure regulation. For patients with angina, it helps reduce the frequency and severity of these painful episodes. It may assist with maintaining a more regular heart rhythm in patients experiencing certain cardiac rhythm irregularities. In clinical settings, Betacar supports long-term stability in patients who are hemodynamically stable.


Quick Fact: Relief for Cardiovascular Symptoms This medication contributes to improved comfort and assists with maintaining functional stability by easing symptoms related to heightened physiological activity.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Betacar (Atenolol) eligibility is defined by specific rules from regulatory authorities, primarily restricting use in certain cardiovascular, metabolic, and age groups. It is approved for use in adults but is not recommended for the pediatric population due to a lack of established safety and efficacy data.

Populations for Whom Use is Contraindicated

The medicine must not be used by patients who have a known hypersensitivity to Atenolol or those with certain severe conditions, including second or third-degree heart block, cardiogenic shock, sinus bradycardia (heart rate too slow), uncontrolled heart failure, sick sinus syndrome, and metabolic acidosis.

Condition-Specific Eligibility Rules

Eligibility is restricted for patients with renal impairment, as Betacar is primarily eliminated by the kidneys. Significant accumulation occurs when Creatinine Clearance is below 35 mL/min, requiring a reduced dose. Caution is also advised in patients with diabetes, as the medicine may mask symptoms of hypoglycemia.

Pregnancy and Lactation Eligibility Status

Use during the second and third trimesters of pregnancy is not recommended due to associated risks of fetal growth restriction. The drug is excreted into breast milk, and its use requires caution when breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Betacar (Atenolol) is primarily defined by documented effects on cardiac function and alterations in drug exposure, based on official regulatory information. No specific drug-drug combination is universally classified as a formal contraindication; restrictions apply to heightened risk areas.

Pharmacodynamic and Absorption Interactions

Classification Interacting Substance/Category Official Documented Outcome
Pharmacodynamic Synergism Calcium Channel Blockers (e.g., Verapamil, Diltiazem), Antiarrhythmics (e.g., Amiodarone) Increased risk of severe bradycardia and AV conduction abnormalities due to additive effects on the heart.
Pharmacodynamic Antagonism Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Decreased antihypertensive effect, particularly with chronic use.
Absorption Interference Aluminum Hydroxide (Antacids), Multivitamins with Minerals, Calcium Salts Reduced systemic exposure (decreased plasma levels) due to inhibited gastrointestinal absorption.

Timing and Procedural Constraints

Administration of Betacar must be separated by at least 2 hours from the intake of Aluminum Hydroxide or Multivitamins with Minerals to mitigate the documented reduction in absorption. In cases of concurrent therapy, Betacar must be discontinued several days prior to the scheduled withdrawal of Clonidine to reduce the risk of rebound hypertension. Furthermore, Alcohol (Ethanol) is documented to have additive effects in lowering blood pressure. Since Atenolol is primarily eliminated by the kidneys, patients with Renal Impairment may experience increased effects due to slower clearance, as noted in the prescribing information.

Mechanism of Action

How Betacar Works

Betacar functions as a small molecule antagonist, exerting its initial effect by binding reversibly to the A1 R receptor. This molecular interaction immediately prevents ligand binding and conformationally blocks the receptor's activity, which initiates the intracellular pharmacodynamic mechanism.

The immediate consequence of A1 R blockade is a resulting decrease in the activity of protein kinase C ( PKC). By inhibiting PKC signaling, Betacar influences the complex cellular pathways associated with bone remodeling. This mechanism continues the signaling cascade through the subsequent modulation of various downstream transcription factors, ultimately resulting in a sustained change in physiological cellular function.

Dosage and Administration Information

Official Administration Guidelines for Betacar (Atenolol)

Betacar is administered using two officially approved routes: the oral tablet for long-term chronic management and the intravenous (IV) injection for immediate, acute hospital intervention. The official usage instructions strictly define the appropriate dose, frequency, and administration conditions for each application.

Usage Condition Standard Labeled Regimen Administration Rules
Chronic Oral Dosing Initiate at 50 mg once daily. May be increased to a maintenance dose of 100 mg once daily after one to two weeks if needed. Tablets may be taken with or without food. Administration should occur at the same time each day for consistency.
Acute IV/Oral Protocol Initial 5 mg IV injection over 5 minutes, repeated after 10 minutes. Followed by 50 mg oral tablet 10 minutes after the final IV dose, then 100 mg daily for 6 -9 days. Initial IV phase requires hospital supervision and is specific to acute post-event care.

Procedural and Population-Specific Instructions

Renal Impairment: Dosing must be adjusted for patients with reduced kidney function, as Atenolol is primarily eliminated by the kidneys. The maximum oral dose is restricted to 50 mg daily for a creatinine clearance of 15 -35 mL/min and 25 mg daily for a clearance below 15 mL/min.

Discontinuation: Treatment must not be stopped suddenly. Official instructions mandate that the dose be gradually reduced (tapered) over a period of one to two weeks.

Missed Dose: If an oral dose is missed, it should be taken as soon as remembered, unless it is nearly time for the next scheduled dose, in which case the missed dose must be skipped. Do not take a double dose to make up for a missed one.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Betacar


Evidence for use in conditions characterized by High Blood Pressure (Hypertension)

Research exploring Betacar for use in conditions characterized by high blood pressure relies on a large body of evidence, primarily drawing from Randomized Controlled Trials (RCTs). These studies were designed to explore how the medication influenced both systolic and diastolic blood pressure readings in the observed populations. These findings were often synthesized in systematic reviews and meta-analyses, which combine results from multiple trials.

Studies monitored physiological strain or stress by observing responses over defined time intervals. In these research contexts, research examined how symptoms change over time, focusing on changes in measured blood pressure levels. The research highlights changes measured during the study period related to blood pressure levels. Research also examined the long-term impact on the occurrence of major outcomes such as stroke and myocardial infarction.


Evidence for use in Managing Chest Pain (Angina Pectoris)

For patients with chest pain due to angina, research explored how symptoms evolved in the observed populations, and this evidence comes mainly from short-term and intermediate-term Randomized Controlled Trials. These trials focused on conditions characterized by fluctuating or episodic manifestations, and studies monitored outcomes related to physical discomfort.

Research examined its role in these trials assessing short-term or episodic symptom patterns, focusing on the frequency and severity of anginal episodes. Researchers also used controlled exercise tests to measure outcomes reflecting daily functioning or activity level, such as the total time a patient could exercise before symptoms began. Evidence is often based on short-term symptom relief, and follow-up durations were limited for long-term prognosis.


What is Still Uncertain About the Research for Betacar

While extensive research is available, there are limitations and areas where scientific discussion continues. For the hypertension indication, studies suggest that while blood pressure reduction was observed, the certainty remains low regarding the consistency of reported outcomes for reducing cardiovascular events (like stroke) when compared to findings from studies of other antihypertensive drug classes.

Furthermore, long-term effects are not fully established for all potential outcomes or special populations, and follow-up durations were limited in many symptom-focused studies. Research provides context but not individual predictions, and study results reflect the specific conditions under which they were conducted.

Key Studies & References

  1. Atenolol - StatPearls (NIH)
  2. Atenolol Oral Tablet (NIH MedlinePlus)

Frequently Asked Questions (FAQ)

Common questions about Betacar (FAQ)

Q: How quickly do the effects of Betacar typically start?

A: According to official product information, a significant beta-blocking effect of Betacar is usually apparent within one hour after taking an oral dose. This effect typically reaches its maximum level at about two to four hours after ingestion.

Q: Is Betacar the same as [Brand Name of similar drug]?

A: The active ingredient in Betacar is Atenolol. This is the generic drug name. Atenolol is widely available under various brand names globally, but the active chemical compound and its therapeutic classification remain the same.

Q: Can Betacar be taken by people who have asthma?

A: Official warnings state that use may be restricted or require caution for patients who have existing conditions affecting the airways, such as asthma or bronchospasm. This is due to the potential for the medicine to exacerbate these respiratory conditions.

Q: How long does Betacar usually stay in your system?

A: Regulatory documents indicate that the elimination half-life of the drug is approximately 6 to 7 hours. However, the beneficial effects, such as lowering blood pressure, are often shown to persist for at least 24 hours after taking a single daily dose.

Q: Can women who are pregnant or breastfeeding use Betacar?

A: Official guidance advises against using Betacar during the second and third trimesters of pregnancy due to potential risks to the developing fetus. The drug is known to be excreted into breast milk, and caution is therefore advised during lactation due to the risk of the drug affecting the infant.

Q: Can Betacar affect my ability to drive or operate machinery?

A: Regulatory documents describe side effects such as dizziness or tiredness, which are known to potentially affect the ability to drive or operate machinery.

Q: Can Betacar interact with herbal supplements?

A: Authoritative sources note that because herbal remedies and supplements are not tested like prescription drugs, formal studies are typically unavailable to confirm potential interactions when taken concurrently with this drug class.

Q: Why might a doctor switch me from one beta-blocker to Betacar?

A: Betacar (Atenolol) is classified as a cardioselective beta-blocker, meaning it primarily focuses its action on the receptors in the heart. Differences in the specific way various beta-blockers work are a documented factor when considering alternative therapy.

Q: Does Betacar cause hair loss?

A: Hair loss, or alopecia, has been reported in post-marketing experience for Betacar. It is generally listed as a possible side effect, though official reports indicate the frequency is typically rare.

Q: Is Betacar used for treating heart rhythm issues?

A: Yes. Official documents confirm that in addition to its uses for high blood pressure and chest pain, the drug is used for managing certain types of irregular heartbeats, known as supraventricular and ventricular tachyarrhythmias.

Q: Is Betacar a controlled substance?

A: Betacar, which contains Atenolol, is a prescription-only medicine but is not classified as a controlled substance under the U.S. Drug Enforcement Administration (DEA) scheduling system.

Q: What is the general expectation for how long I can expect to be on Betacar?

A: Official documentation indicates that the medicine is approved for the management of chronic conditions such as high blood pressure and angina, which is consistent with a treatment strategy that may require long-term use. It is also approved for a short course of 6–9 days after a heart attack.

Q: Are allergic reactions to Betacar common?

A: Severe allergic reactions are considered rare, but the medication is strictly contraindicated (must not be used) in patients who have a known hypersensitivity to the active ingredient. Less severe adverse reactions such as skin rashes have been reported.

Q: Is Betacar only for high blood pressure?

A: No. Official documents confirm that Betacar is approved for managing high blood pressure, relieving chest pain (angina pectoris), and reducing risks after an acute myocardial infarction (heart attack).

Q: Can Betacar affect athletic performance?

A: Since the drug works by slowing the heart rate, official research has shown that it can cause a reduction in the body’s ability to tolerate exercise (exercise endurance capacity) compared to not taking the drug.

Q: Is there a generic version of Betacar available?

A: Yes, the active ingredient in Betacar is Atenolol, which is widely available as a generic medication.

Q: Does Betacar affect blood sugar levels?

A: Official warnings state that for patients with diabetes, the drug may mask certain typical symptoms of acute hypoglycemia (low blood sugar), such as a rapid heart rate or tremors, making the condition harder to recognize.

Q: Are headaches a common side effect of Betacar?

A: Headaches have been listed in post-marketing reports as a possible side effect. However, they are not typically reported as frequently as other nervous system side effects like dizziness and fatigue.

Q: Can Betacar cause weight gain?

A: Official patient information notes that unusual weight gain is listed as a possible side effect. This is a possibility that has been reported with older beta-blockers, such as Betacar (Atenolol).

Q: Is Betacar considered a first-line treatment for its main uses?

A: Betacar remains a foundational drug for cardiovascular support. However, current professional guidelines generally no longer recommend beta-blockers like Betacar as the first-line (or initial) therapy for all cases of uncomplicated high blood pressure.

Q: What are the most serious, but rare, side effects mentioned in official texts?

A: Official texts mention several serious, clinically significant risks. These include the potential for a severe gastrointestinal reaction called sprue-like enteropathy, severe heart block, and an acute worsening of heart conditions if the drug is stopped suddenly.

How should Betacar be stored and disposed of?

How to Store and Dispose of Betacar (Atenolol Tablets)

Storage Requirement Condition as Stated in Regulatory Documents
Temperature Store at room temperature, not above 25 C.
Environmental Protection Protect from excess heat, moisture, and direct light; must not freeze.
Packaging Keep the container tightly closed and store in the original package.

This medicine must be stored strictly according to official regulatory specifications to maintain its stability. It is a mandatory requirement to keep this medicine out of the sight and reach of children at all times.

For disposal, Betacar tablets must not be thrown away via waste water or household waste. Any unused product or waste material must be disposed of in accordance with local requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Betacar found in:

A-Z Index: